BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

928 related articles for article (PubMed ID: 29360550)

  • 1. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
    Wardell CP; Fujita M; Yamada T; Simbolo M; Fassan M; Karlic R; Polak P; Kim J; Hatanaka Y; Maejima K; Lawlor RT; Nakanishi Y; Mitsuhashi T; Fujimoto A; Furuta M; Ruzzenente A; Conci S; Oosawa A; Sasaki-Oku A; Nakano K; Tanaka H; Yamamoto Y; Michiaki K; Kawakami Y; Aikata H; Ueno M; Hayami S; Gotoh K; Ariizumi SI; Yamamoto M; Yamaue H; Chayama K; Miyano S; Getz G; Scarpa A; Hirano S; Nakamura T; Nakagawa H
    J Hepatol; 2018 May; 68(5):959-969. PubMed ID: 29360550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
    Okawa Y; Iwasaki Y; Johnson TA; Ebata N; Inai C; Endo M; Maejima K; Sasagawa S; Fujita M; Matsuda K; Murakami Y; Nakamura T; Hirano S; Momozawa Y; Nakagawa H
    J Hepatol; 2023 Feb; 78(2):333-342. PubMed ID: 36243179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational spectrum and precision oncology for biliary tract carcinoma.
    Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
    Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
    Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
    JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract.
    Roos E; Soer EC; Klompmaker S; Meijer LL; Besselink MG; Giovannetti E; Heger M; Kazemier G; Klümpen HJ; Takkenberg RB; Wilmink H; Würdinger T; Dijk F; van Gulik TM; Verheij J; van de Vijver MJ
    Crit Rev Oncol Hematol; 2019 Aug; 140():8-16. PubMed ID: 31158800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS Allelic Variants in Biliary Tract Cancers.
    Moffat GT; Hu ZI; Meric-Bernstam F; Kong EK; Pavlick D; Ross JS; Murugesan K; Kwong L; De Armas AD; Korkut A; Javle M; Knox JJ
    JAMA Netw Open; 2024 May; 7(5):e249840. PubMed ID: 38709532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.
    Maynard H; Stadler ZK; Berger MF; Solit DB; Ly M; Lowery MA; Mandelker D; Zhang L; Jordan E; El Dika I; Kemel Y; Ladanyi M; Robson ME; O'Reilly EM; Abou-Alfa GK
    Cancer; 2020 Jan; 126(9):1995-2002. PubMed ID: 32012241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis.
    Min BJ; Kang YK; Chung YG; Seo ME; Chang KB; Joo MW
    Clin Orthop Relat Res; 2020 Nov; 478(11):2442-2450. PubMed ID: 32281771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M; Heumann T; Goff L; Agarwal R
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal analysis of metachronous double biliary tract cancers.
    Omori Y; Aoki S; Ono Y; Kokumai T; Yoshimachi S; Sato H; Kusaka A; Iseki M; Douchi D; Miura T; Maeda S; Ishida M; Mizuma M; Nakagawa K; Mizukami Y; Furukawa T; Unno M
    J Pathol; 2024 May; 263(1):113-127. PubMed ID: 38482714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
    Yu H; Xu Y; Gao W; Li M; He J; Deng X; Xing W
    Front Oncol; 2022; 12():930611. PubMed ID: 36072793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into molecular and immune subtypes of biliary tract cancers.
    Bramel ER; Sia D
    Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.
    Ahn DH; Javle M; Ahn CW; Jain A; Mikhail S; Noonan AM; Ciombor K; Wu C; Shroff RT; Chen JL; Bekaii-Saab T
    Cancer; 2016 Dec; 122(23):3657-3666. PubMed ID: 27495988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
    Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
    J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biliary tract cancers : Molecular characterization and identification of novel prognostic markers].
    Goeppert B
    Pathologe; 2017 Nov; 38(Suppl 2):192-197. PubMed ID: 29063951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.
    Chen X; Wang D; Liu J; Qiu J; Zhou J; Ying J; Shi Y; Wang Z; Lou H; Cui J; Zhang J; Liu Y; Zhao F; Pan L; Zhao J; Zhu D; Chen S; Li X; Li X; Zhu L; Shao Y; Shu Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomics driven precision oncology in advanced biliary tract cancer improves survival.
    Kumar-Sinha C; Vats P; Tran N; Robinson DR; Gunchick V; Wu YM; Cao X; Ning Y; Wang R; Rabban E; Bell J; Shankar S; Mannan R; Zhang Y; Zalupski MM; Chinnaiyan AM; Sahai V
    Neoplasia; 2023 Aug; 42():100910. PubMed ID: 37267699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
    Tang TY; Nichetti F; Kaplan B; Lonardi S; Pietrantonio F; Salvatore L; Vivaldi C; Rimassa L; de Braud F; Rizzato MD; Pavlick D; Chu R; Danner De Armas A; Sharaf R; Sokol E; Rodon Ahnert J; Ross JS; Javle M; Niger M
    Clin Cancer Res; 2023 Dec; 29(23):4853-4862. PubMed ID: 37773629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.